Preventing cognitive decline and dementia from cerebral small vessel disease: The LACI-1 Trial. Protocol and statistical analysis plan of a phase IIa dose escalation trial testing tolerability, safety and effect on intermediary endpoints of isosorbide mononitrate and cilostazol, separately and in combination. (2018)

First Author: Blair GW
Attributed to:  Centre for Cognitive Ageing & Cognitive Epidemiology funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1177/1747493017731947

PubMed Identifier: 28906205

Publication URI: http://europepmc.org/abstract/MED/28906205

Type: Journal Article/Review

Volume: 13

Parent Publication: International journal of stroke : official journal of the International Stroke Society

Issue: 5

ISSN: 1747-4930